Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...

China’s exports surged as shipments to Southeast Asian countries soared, offsetting a sharp drop in outbound goods to the U.S ...

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...

The president is planning Monday to revive a plan from his first term, which would peg the prices the United States pays for ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

The announcement has sent share prices of pharmaceuticals companies around the world tumbling. Japanese companies Chugai ...

Trump’s drug pricing order sparks global pharma sell-off as industry warns of stifled innovation and revenue loss in key US ...

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration ...